Literature DB >> 6201549

Stimulation of natural killer cells in two random-bred strains of athymic rats by interferon-inducing pyrimidinone.

E Lotzová, C A Savary, A Khan, D A Stringfellow.   

Abstract

We tested the effect of 2-amino-5-bromo-6 phenyl-4 pyrimidinol (ABPP), an interferon (IFN) inducer, on NK cell cytotoxicity in various tissues of athymic and euthymic rats. Significant augmentation of NK cell cytotoxicity was observed in SP, PB, PE, lung, and liver of adult rats. Cytotoxic potential was also induced by ABPP in young rats, not exhibiting cytotoxicity before the treatment. Cytotoxic cells were detected in nylon wool-filtered fraction, and were not removed by carbonyl iron treatment. Separation on Percoll gradient indicated that ABPP-stimulated cytotoxic SPC resided in LGL-enriched fractions and some of them exhibited less dense characteristics than SPC from untreated rats. The ABPP-mediated cytotoxicity was thymus-independent; both athymic and euthymic rats were equally augmented. The observation that only tissues displaying NK cell augmentation produced significant levels of IFN suggest possible involvement of IFN in ABPP-mediated augmentation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201549

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The antitumour activity of the interferon inducer bropirimine is partially mediated by endogenous tumour necrosis factor alpha.

Authors:  M Scheringa; J N IJzermans; J Jeekel; R L Marquet
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.

Authors:  Michael F Sarosdy; Catherine M Tangen; Geoffrey R Weiss; Blake R Nestok; Mitchell C Benson; Paul F Schellhammer; Arthur I Sagalowsky; David P Wood; E David Crawford
Journal:  Urol Oncol       Date:  2005 Nov-Dec       Impact factor: 3.498

Review 3.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

4.  Toll-like receptors: role in dermatological disease.

Authors:  Aswin Hari; Tracy L Flach; Yan Shi; P Régine Mydlarski
Journal:  Mediators Inflamm       Date:  2010-08-22       Impact factor: 4.711

5.  Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases.

Authors:  M S Roh; M P Kahky; C Oyedeji; J Klostergaard; L Wang; S A Curley; E Lotzová
Journal:  Clin Exp Metastasis       Date:  1992-09       Impact factor: 5.150

7.  Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.

Authors:  T Fujioka; K Ishikura; M Hasegawa; K Ogyu; Y Matsushita; M Sato; F Sato; H Aoki; T Kubo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Site-specific antitumour effects of 2 pyrimidinone compounds in rats.

Authors:  A M Eggermont; R L Marquet; R W De Bruin; W Weimar; J Jeekel
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

Review 9.  Biologic response modifiers in the management of superficial bladder cancer.

Authors:  S Serels; J Fleischmann
Journal:  World J Urol       Date:  1997       Impact factor: 3.661

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.